Cargando…
Checkpoint blockade in the treatment of breast cancer: current status and future directions
There is now accumulating evidence that the host immune system plays an important role in influencing response to treatment and prognosis in breast cancer. Immunotherapy with immune checkpoint inhibitors is a promising and rapidly growing field of interest in many solid tumours, including breast can...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035268/ https://www.ncbi.nlm.nih.gov/pubmed/29808015 http://dx.doi.org/10.1038/s41416-018-0126-6 |
_version_ | 1783338020094607360 |
---|---|
author | Wein, Lironne Luen, Stephen J Savas, Peter Salgado, Roberto Loi, Sherene |
author_facet | Wein, Lironne Luen, Stephen J Savas, Peter Salgado, Roberto Loi, Sherene |
author_sort | Wein, Lironne |
collection | PubMed |
description | There is now accumulating evidence that the host immune system plays an important role in influencing response to treatment and prognosis in breast cancer. Immunotherapy with immune checkpoint inhibitors is a promising and rapidly growing field of interest in many solid tumours, including breast cancer. Trials to date have largely focused on metastatic triple-negative disease, a genomically unstable subtype of breast cancer that is believed to be the most immunogenic and following the development of treatment resistance, has limited treatment options and a particularly poor prognosis. Both checkpoint inhibitor monotherapy and combinations with chemotherapy are being investigated. In this review, we discuss the current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting. We also propose potential ways of improving responses to checkpoint blockade in breast cancer. |
format | Online Article Text |
id | pubmed-6035268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60352682019-07-03 Checkpoint blockade in the treatment of breast cancer: current status and future directions Wein, Lironne Luen, Stephen J Savas, Peter Salgado, Roberto Loi, Sherene Br J Cancer Review Article There is now accumulating evidence that the host immune system plays an important role in influencing response to treatment and prognosis in breast cancer. Immunotherapy with immune checkpoint inhibitors is a promising and rapidly growing field of interest in many solid tumours, including breast cancer. Trials to date have largely focused on metastatic triple-negative disease, a genomically unstable subtype of breast cancer that is believed to be the most immunogenic and following the development of treatment resistance, has limited treatment options and a particularly poor prognosis. Both checkpoint inhibitor monotherapy and combinations with chemotherapy are being investigated. In this review, we discuss the current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting. We also propose potential ways of improving responses to checkpoint blockade in breast cancer. Nature Publishing Group UK 2018-05-29 2018-07-03 /pmc/articles/PMC6035268/ /pubmed/29808015 http://dx.doi.org/10.1038/s41416-018-0126-6 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/S.J.L. is supported by the University of Melbourne. S.L. is supported by the Cancer Council Victoria John Colebatch fellowship, the Breast Cancer Research Foundation (BCRF) NY, the National Health and Medical Research Council (NHMRC) of Australia. R.S. is supported by the BCRF. Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Review Article Wein, Lironne Luen, Stephen J Savas, Peter Salgado, Roberto Loi, Sherene Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title_full | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title_fullStr | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title_full_unstemmed | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title_short | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
title_sort | checkpoint blockade in the treatment of breast cancer: current status and future directions |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035268/ https://www.ncbi.nlm.nih.gov/pubmed/29808015 http://dx.doi.org/10.1038/s41416-018-0126-6 |
work_keys_str_mv | AT weinlironne checkpointblockadeinthetreatmentofbreastcancercurrentstatusandfuturedirections AT luenstephenj checkpointblockadeinthetreatmentofbreastcancercurrentstatusandfuturedirections AT savaspeter checkpointblockadeinthetreatmentofbreastcancercurrentstatusandfuturedirections AT salgadoroberto checkpointblockadeinthetreatmentofbreastcancercurrentstatusandfuturedirections AT loisherene checkpointblockadeinthetreatmentofbreastcancercurrentstatusandfuturedirections |